Results 21 to 30 of about 441,361 (298)

Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.

Circulation Research, 2020
Anthracycline-based chemotherapy can result in the development of a cumulative and progressively developing cardiomyopathy. Doxorubicin is one of the most highly prescribed anthracyclines in the United States due to its broad spectrum of therapeutic ...
K. Wallace, V. Sardão, P. Oliveira
semanticscholar   +1 more source

Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy

Circulation: Heart Failure, 2020
Supplemental Digital Content is available in the text.
E. Ammirati, M. Frigerio, E. Adler, C. Basso, D. Birnie, M. Brambatti, M. Friedrich, K. Klingel, J. Lehtonen, J. Moslehi, P. Pedrotti, O. Rimoldi, H. Schultheiss, C. Tschöpe, L. Cooper, P. Camici   +15 more
semanticscholar   +1 more source

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation, 2020
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting ...
S. Ommen, S. Mital, Michael A. Burke, S. Day, A. Deswal, P. Elliott, Lauren L. Evanovich, J. Hung, J. Joglar, P. Kantor, C. Kimmelstiel, M. Kittleson, M. Link, M. Maron, Matthew W. Martinez, C. Miyake, H. Schaff, C. Semsarian, Sorajja Paul   +18 more
semanticscholar   +1 more source

Hospital Procedural Volume and Clinical Outcomes Following Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Prior national data showed a substantial in‐hospital mortality in septal myectomy (SM) with an inverse volume–outcomes relationship. This study sought to assess the contemporary outcomes of septal reduction therapy and volume–outcome ...
Ahmed M. Altibi, Fares Ghanem, Yuanzi Zhao, Miriam Elman, Joaquin Cigarroa, Babak Nazer, Howard K. Song, Ahmad Masri   +7 more
doaj   +1 more source

Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy

Circulation, 2020
Supplemental Digital Content is available in the text. Background: Mutations in desmoplakin (DSP), the primary force transducer between cardiac desmosomes and intermediate filaments, cause an arrhythmogenic form of cardiomyopathy that has been variably ...
Eric Smith, N. Lakdawala, N. Papoutsidakis, G. Aubert, A. Mazzanti, Anthony C McCanta, P. Agarwal, P. Arscott, Lisa M. Dellefave‐Castillo, E. Vorovich, K. Nutakki, Lisa D. Wilsbacher, S. Priori, D. Jacoby, E. McNally, A. Helms   +15 more
semanticscholar   +1 more source

Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy

Scientific Reports, 2021
Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity. We investigated the molecular basis of the cardiac phenotype in two mouse models at established disease stage (mouse-HCM), and human myectomy tissue (human-HCM).
Styliani Vakrou, Yamin Liu, Li Zhu, Gabriela V. Greenland, Bahadir Simsek, Virginia B. Hebl, Yufan Guan, Kirubel Woldemichael, Conover C. Talbot, Miguel A. Aon, Ryuya Fukunaga, M. Roselle Abraham   +11 more
doaj   +1 more source

Availability and Utilization of Automated External Defibrillators in New York State Schools

Frontiers in Pediatrics, 2021
Background: Use of automated external defibrillators (AEDs) in out-of-hospital cardiac arrests (OHCAs) improve survival. Professional health organizations recommend that AEDs be available in crowded places, including schools but currently only 18 US ...
Milla Arabadjian, Milla Arabadjian, Stephanie Serrato, Mark V. Sherrid   +3 more
doaj   +1 more source

Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2016
BackgroundThe subcutaneous implantable cardioverter defibrillator (S‐ICD) has been developed to avert risks associated with transvenous defibrillator leads. The technology is attractive for younger patients, such as those with hypertrophic cardiomyopathy
Jonathan Weinstock, Yousef H. Bader, Martin S. Maron, Ethan J. Rowin, Mark S. Link   +4 more
doaj   +1 more source

Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Genetic testing for hypertrophic cardiomyopathy (HCM) is an established clinical technique, supported by 30 years of research into its genetic etiology.
Francesco Mazzarotto, Iacopo Olivotto, Beatrice Boschi, Francesca Girolami, Corrado Poggesi, Paul J. R. Barton, Roddy Walsh   +6 more
doaj   +1 more source

Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy

Journal of Nanobiotechnology, 2018
Background Theranostic perfluorocarbon nanoprobes have recently attracted attention due to their fascinating versatility in integrating diagnostics and therapeutics into a single system.
Xueli Zhao, Wen Luo, Jing Hu, Lei Zuo, Jing Wang, Rui Hu, Bo Wang, Lei Xu, Jing Li, Meng Wu, Pan Li, Liwen Liu   +11 more
doaj   +1 more source